| Micro-channel |
 |
|
|
|
|
|
| |
| The ministry of industry and information technology (mii) has subsidized 550 million Chinese traditional Chinese medicine varieties with the most opportunity (list) |
| |
| Author：中國銘鉉 企劃部 Release Time：2017-8-28 10:09:02 Number Browse：705 |
| |
On August 28, the pharmaceutical network upgraded the traditional Chinese medicine industrial technology upgrading and service guarantee to do 5 things.
Recently, the ministry of industry and the ministry of industry and information technology released about 2017 industrial transformation and upgrading (2025) made in China funds (budgets) project guide notice (notice), for the full implementation of China's manufacturing 2025 development strategy, accelerate the supply side structural reform, promoting the transformation and upgrading of the industry, invigorate the economy, the ministry of industry and information technology decided to organize the implementation of industrial transformation and upgrading in 2017 (2025) made in China funds (budgets) key projects.
According to the notice, the state plans to finance 25 projects related to the 2017 industrial transformation and upgrading (made in China 2025) strategy.
Among them, there are 6 items related to medicine -- except for a shortage of drugs, which are related to the traditional Chinese medicine industry, which can be seen in the importance of the transformation and upgrading of the traditional Chinese medicine industry.
On the basis of the support and financing of Chinese traditional medicine preparations and traditional Chinese medicine, the total subsidy project is around 11, with a planned investment of about 550 million yuan.
To inform the related tasks and support of the Chinese medicine industry:
(note: the information is from the website of the ministry of industry and information technology)
▍ good traditional Chinese medicine industry policy
The country has promoted the development of traditional Chinese medicine to the important position of national strategy.
Since March 25, 2013, the state administration of traditional Chinese medicine issued the prevention of traditional Chinese medicine health care (not cure disease) service outline (2013-2020), "science and technology innovation, to the end of 2016, has been formally come into effect on July 1, the law of the People's Republic of China law of traditional Chinese medicine, to the support of traditional Chinese medicine is upgraded to the height of the law.
According to the author preliminary incomplete statistics, in just two years the central ministries and place in the development of TCM industry support policy documents released more than 50 copies of both the upper reaches of the medicinal materials planting protection link related planning and policy, also have a middle medicinal materials circulation and trade link policy and opinion.
6 months, the state ministry of science and technology publishing much starker choices-and graver consequences-in "special planning of scientific and technological innovation of Chinese medicine, clearly put forward in" much starker choices-and graver consequences-in "into an output value exceeding 1 billion yuan during the period of traditional Chinese medicine health products group of 3-5, international famous brand 1-2.
Ministry recently issued the "ministry of industry and information technology released about 2017 industrial transformation and upgrading (2025) made in China funds (budgets) project guide notice, but specific subsidy project are presented for the development of traditional Chinese medicine (TCM) to the number of projects and standards.
▍ these herbs large varieties and the enterprise or the best chance of funding support
In the miit notice, specifically: varieties of traditional Chinese medicines technology to promote medicine directory, sales income of more than 300 million varieties of priority given funding for technology promotion, is enterprise of Chinese herbal medicine industry will be preferred.
According to the above criteria, 19 drugs were selected, and the total sales revenue of these drugs in 2016 was more than 300 million, and all were listed in the national 2012 edition.
Of these, oral medication accounted for most of the total, 11 of them, 7 of them and 1 of them.
Enterprises, tasly, step length, compared to all have two products on the list, and these enterprises is not only the top of the traditional Chinese medicine industry in China, is also China's pharmaceutical industry enterprises, and these big projects opportunities is more, big companies, but Chinese medicine development in the field of benchmarking enterprise, these enterprises the best chance of get funding opportunities.
The details of these varieties and enterprises are as follows:
(note: the data comes from the annual report of each listed company, and some varieties of data are calculated according to the sales volume, which are ranked by the sales revenue;Data for reference)
▍ Chinese medicine yinpian industry concentration will improve, leading enterprises or further expansion
Recently, the ministry has released the first half of 2017 economic indicators of pharmaceutical industry in China, Chinese medicine yinpian is the fastest developing sector, with the country in recent years, big strong policy support are inseparable.
Speaking of the representative of traditional Chinese medicine and beverage industry, there is no doubt that kangmei pharmaceutical co., which has the advantage of the development of Chinese medicinal materials and the development of Chinese medicine, has an advantage in the technology and the whole industry chain.
Pilot open policy in guangdong province traditional Chinese medicine formula particles within 10 days after release, sig pharmaceutical to pilot production and sales of traditional Chinese medicine formula particles qualification, industrial chain integration ability, it also for the development of the Chinese medicine yinpian plate opens up new areas of growth.
In recent days, kangmei is listed as the top 50 listed company in Asia in 2017 (click to read: 5 pharmaceutical companies are listed in Forbes Asia's best), so it can see its potential.
In addition, the sig pharmaceutical industry with Chinese herbal medicine information portal and the third-party service trading platform sig Chinese materia medica industry network, has a more solid data base, also built higher barriers to sustainable development in the future.
(note: the data comes from the company's annual report)
|
| |
Previous article：Two ticket-system supplementary documents are being worked out!Some terms are basically confirmed
Next article：The CFDA makes a clear and consistent evaluation of the declaration requirements, and the labeling is issued through the consistency evaluation
|
| |
|
|
